Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 279 participants.

Also called NCT01620489

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 279 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01620489
  • EudraCT 2011-002968-24
Other papers using this trial's data
  • Comparison of Adherence to Glimepiride/Metformin Sustained Release Once-daily Versus Glimepiride/Metformin Immediate Release BID Fixed-combination Therapy Using the Medication Event Monitoring System in Patients With Type 2 Diabetes Clinical therapeutics, 2018-05 DOI, PubMed 29729957
  • Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial Diabetes care, 2016-02 DOI, PubMed 26681713
  • Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment Diabetes, obesity & metabolism, 2019-05 DOI, PubMed 30663196, PMC6593738 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, France, Poland, Russia, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01620489. Randomized; double masking; primary purpose treatment. Start 2012-06-14 (actual); primary completion 2013-08-20 (actual). Results posted on 2014-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01620489
Content hash
fe94ffd94992ee9244361045f5b13777d6d25b82a3b0cbfcca9a1ec10ac55a52